GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.
It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
The weight of being a Hollywood star can take a toll on a person’s weight.In an industry obsessed with physical appearance, a ...
Hosted on MSN16h
Allurion’s weight loss balloon back on French marketAllurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...
Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback